Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome

Arthritis research & therapy (Impact Factor: 3.75). 10/2013; 15(5):R149. DOI: 10.1186/ar4332
Source: PubMed


The aims of this present study were firstly to assess the outcome, including functional course, in anti-Jo1 positive patients with antisynthetase syndrome (ASS), and secondly to determine predictive parameters of poor outcome in these patients.
The medical records of 86 consecutive anti-Jo1 patients with ASS were reviewed in 4 academic centers.
13 patients (15.1%) achieved remission of ASS, whereas 55 (63.9%) improved and 18 (20.9%) deteriorated in their clinical status. Both steroid and cytotoxic drugs could be discontinued in only 4.7% of patients. ASS was associated with decreased quality of life at long-term follow-up: only 69.2% of patients considered to be in remission experienced a return to previous normal activities; and 24.7% of other patients with non-remitting ASS still had a marked reduction of activities (as shown by the disability scale of the Health Assessment Questionnaire). Decreased quality of life was further due to calcinosis cutis (8.1%) and adverse effects of steroid therapy (36%). Factors associated with ASS deterioration were older age, pulmonary and esophageal involvement, calcinosis cutis and cancer. Higher anti-Jo1 levels were further associated with disease severity in ASS patients.
The present study shows high morbidity related to ASS. Furthermore, we suggest that patients with predictive factors of ASS deterioration may require more aggressive therapy. Our findings also suggest that in anti-Jo1 patients with severe esophageal manifestations, combined high dose steroids and intravenous immunoglobulins might be proposed as the first line therapy. Finally, as cancer occurred in 14% of anti-Jo1 patients, our findings underscore that the search for cancer should be performed in these patients.

Download full-text


Available from: Pierre‐Yves Hatron, Mar 20, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To assess the long-term outcome in polymyositis (PM) and dermatomyositis (DM), with particular emphasis to mortality and influence of treatment. Methods Diagnosis was based according to the Bohan and Peter’s criteria. Patients have been followed by a standardised protocol. Deaths were registered and causes of death ascertained. Survival probability at 5 and 10 years was estimated according to Kaplan-Meier method, in the overall series and by diagnostic group and initial treatment. Mortality hazard ratios (95% CI) for major clinical and demographic features were estimated through univariate and multivariate Cox proportional hazard models. Results 91 patients (43 PM and 48 DM) were available for the study. Baseline characteristics were not different from those previously reported. Twenty-two patients (24%) died after a median follow-up of 8.7 years. As for idiopathic myositis, the survival probabilities at 5- and 10-years from the diagnosis were 96.2% and 88.8% for PM respectively; and 93.9% for DM, whereas a higher mortality was documented for cancer-associated and overlap-myositis myositis. Male sex [HR = 2.4, 95% CI 1.0 to 5.6], heart involvement (HR = 1.8), interstitial lung disease (HR = 2.3) and arthritis (HR = 1.8), increased the risk of mortality, these risk excesses were confirmed in multivariate analysis. Independently of these features, a higher mortality was documented for patients treated with glucocorticoids (HR = 2.3) or immunosuppressant (HR = 2.1) versus patients treated with immunoglobulin. Conclusion Our study, with longitudinal and statistical analyses, suggests that survival has considerably increased in patients with PM/DM. Prognostic factors for mortality are male sex, heart and lung involvement. Immunoglobulin treatment, intravenously or subcutaneously, is associated with a better survival.
    Autoimmunity Reviews 10/2014; 13(10). DOI:10.1016/j.autrev.2014.08.023 · 7.93 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Le syndrome des antisynthétases correspond à une myopathie inflammatoire fréquemment associée à une atteinte pulmonaire, surtout parenchymateuse (pneumopathie infiltrante diffuse) et plus rarement vasculaire (hypertension pulmonaire). Devant un tableau clinique et radiologique évocateur, la présence d’anticorps anti-ARNt synthétases signe le diagnostic. Les plus fréquents de ces auto-anticorps sont les anti-Jo1, les anti-PL7 et les anti-PL12. De nombreuses manifestations cliniques extrathoraciques associées à l’atteinte pulmonaire peuvent orienter le diagnostic : myalgies ou déficit musculaire, phénomène de Raynaud, polyarthrite, fièvre et « mains de mécaniciens ». Une augmentation des créatine-phospho-kinases est quasi constante. Le recours à l’électromyogramme, à l’imagerie musculaire par résonance magnétique ou à l’histologie n’est pas systématique. Néanmoins, il existe une grande variabilité des symptômes et de leur sévérité d’un patient à l’autre ou au long de l’évolution de la maladie. L’atteinte pulmonaire est un facteur pronostic majeur et incite à traiter de manière intensive les patients, principalement par corticothérapie systémique, voire d’emblée par association corticoïdes et immunosuppresseurs. Mieux connaître cette pathologie qui est souvent de révélation pneumologique permettrait d’améliorer le diagnostic et la prise en charge thérapeutique, voire même le pronostic.
    Revue des Maladies Respiratoires 10/2014; 2(6). DOI:10.1016/j.rmr.2014.07.013 · 0.62 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Antisynthetase syndrome (ASS) is a rare condition characterized by interstitial lung disease (ILD), inflammatory myositis, fever, Raynaud phenomenon, mechanic's hand, and inflammatory polyarthritis in the setting of antibodies to amino acyl-transfer RNA synthetases, with anti-Jo-1 antibody being the most common. Prognosis is very poor especially when there is associated ILD. To date, there is no standardized treatment for ILD associated ASS. Therapy is based on the use of steroids alone or in combination with other immunosuppressive agents, especially in severe or refractory cases. The role of therapeutic plasma exchange (TPE) in the management of this rare condition has not been established. Here, we report a case of severe ILD associated ASS in a 41-year-old woman who did not show clinical or laboratory response after six doses of high dose steroids and a dose of IV cyclophosphamide. Because of the aggressive nature of her disease and poor prognostic indices present, a decision was made to add TPE to her treatment. She underwent five sessions of TPE. At the end of the 5th session, the anti-Jo-1 antibody levels dropped to 3.6 AI (antibody index) and her creatinine kinase (CK) level from 875 to 399 U L(-1) (Units per liter) with overall improvement in her respiratory status. This case suggests TPE may be a promising treatment option in patients with ILD associated ASS refractory to steroids and other immunosuppressive therapy, particularly those with severe disease. J. Clin. Apheresis, 2015. © 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.
    Journal of Clinical Apheresis 02/2015; DOI:10.1002/jca.21387 · 1.79 Impact Factor
Show more